Conjugation of universal, functionally de-targeted OneAAVTM capsid provides on-demand specificity and scalabilityto address ...
AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one-time gene silencing in the central nervous system AviadoBio will present k ...
Peking University, July 23, 2025: On July 14, 2025, Professor Su Xiaodong’s team from the School of Life Sciences at Peking University, in collaboration with Professor John Rasko’s team from the ...
- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding protein ...
The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
In vitro data demonstratedself-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Newcells’ technical experts precisely outlined the problem and the questions to be answered during an in-depth discussion with the client. The client wanted to quickly determine whether their AAV ...
Dhimiter Bello, Sc.D., M.Sc. (Chair) Jonathan Hill, Ph.D. (industry on site advisor) Soumita Das, Ph.D. Jonghan Kim, Ph.D. Brief Abstract: Adeno-Associated Virus (AAV) vectors are being used in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results